Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Wagner's disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44300   clinical trials with a EudraCT protocol, of which   7354   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    90 result(s) found for: Wagner's disease. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2010-023277-19 Sponsor Protocol Number: Start Date*: 2011-05-05
    Sponsor Name:Med. Univ. Wien, Univ. Klinik für Dermatologie
    Full Title: CD20-Immunotargeting in Stage IV Melanoma Patients- A Prospective, Open Label, Two-Period Pilot Study to Evaluate Overall Tumor Responsive Rate
    Medical condition: Patients suffering from early stage melanoma have a good chance of recovery whereas the 5-year survival rate of patients with metastasized melanomas (stage III and stage IV) is less than 10% for th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005125-30 Sponsor Protocol Number: V1.1 Start Date*: 2008-11-20
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Dermatologie, Abteilung für Immundermatologie
    Full Title: Rituximab (Mabthera) in metastatic melanoma
    Medical condition: metastatic melanoma patients, clinical stage IIIc/IV ( AJCC2002), disease free
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004410-13 Sponsor Protocol Number: 3401 Start Date*: 2008-03-12
    Sponsor Name:Institute od Rheumatology Prague
    Full Title: A PROSPECTIVE, RANDOMISED, ASSESSOR-BLIND, MULTICENTER STUDY OF EFFICACY AND SAFETY OF COMBINED TREATMENT OF METHOTREXATE + GLUCOCORTICOIDS VERSUS GLUCOCORTICOIDS ALONE IN PATIENTS WITH POLYMYOSITI...
    Medical condition: active polymyositis, dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012503 Dermatomyositis LLT
    9.1 10036102 Polymyositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004787-10 Sponsor Protocol Number: C0251008 Start Date*: 2022-03-07
    Sponsor Name:Pfizer Inc.
    Full Title: AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO ADULT PARTICIPANTS ≥18 AND ≤80 WITH ACTIVE DERMATOMYOSITIS.
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) ES (Ongoing) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002758-31 Sponsor Protocol Number: ECD01 Start Date*: 2006-12-22
    Sponsor Name:EPOPLUS GmbH & Co.KG
    Full Title: A randomized, double-blind, multi-centre, placebo-controlled, parallel-group study to examine the efficacy and safety of low dose Epoetin beta on wound healing in diabetes patients with foot ulcer
    Medical condition: wound healing in diabetes patients with foot ulcer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10048037 Wound healing disturbance of LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-006426-43 Sponsor Protocol Number: IPAX-Linz-01 Start Date*: 2022-02-16
    Sponsor Name:Kepler Universitätsklinikum Linz Neuromed Campus
    Full Title: An open label, single arm monocentric phase II study to evaluate safety, tolerability, and preliminary efficacy of carrier-added 4-L- [131I]iodophenylalanine (131I-IPA), administered as sequential ...
    Medical condition: Previously confirmed histological diagnosis of malignant brain tumours (glioma), with current clinical or imaging evidence for first or second recurrence
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005772-34 Sponsor Protocol Number: CL2-78989-010 Start Date*: 2013-06-17
    Sponsor Name:Institut de Recherches Internationales Servier (IRIS)
    Full Title: A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy of gevokizumab 60mg subcutaneously every 4 weeks over 24 weeks in the treatment of patients with polymyositis o...
    Medical condition: Polymyositis / Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10036102 Polymyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) SE (Completed) DE (Prematurely Ended) CZ (Completed) GB (Prematurely Ended) ES (Completed) HU (Completed) BE (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005966-35 Sponsor Protocol Number: KKS/INNERE_A/AML2006 Start Date*: 2006-07-24
    Sponsor Name:Universitätsklinikum Münster
    Full Title: A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in elderly patients with newly diagnosed AML
    Medical condition: Patients older than 60 years with newly diagnosed acute myeloid leukemia (AML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000449-15 Sponsor Protocol Number: DIONYSIUS Start Date*: 2020-12-11
    Sponsor Name:Amsterdam University Medical Centers, location AMC
    Full Title: Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?
    Medical condition: Ischemic diabetic foot ulcers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002710-31 Sponsor Protocol Number: SCGAM-02 Start Date*: 2018-08-20
    Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H
    Full Title: DOUBLE-BLIND, RANDOMIZED, PLACEBO- CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH DERMATOMYOSITIS.
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000391-15 Sponsor Protocol Number: AIFA-2016-02364869 Start Date*: 2018-06-05
    Sponsor Name:Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia
    Full Title: Multicentric, open-label, prospective study of subcutaneous tocilizumab in adult patients with refractory myositis
    Medical condition: Myositis (dermatomyositis [DM] or polymyositis [PM])
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028653 Myositis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10036102 Polymyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006311-21 Sponsor Protocol Number: CBAF312A2202 Start Date*: 2009-07-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis
    Medical condition: Polymyositis and dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036102 Polymyositis LLT
    9.1 10012503 Dermatomyositis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-004228-41 Sponsor Protocol Number: C0251002 Start Date*: 2021-07-28
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000898-83 Sponsor Protocol Number: ADN016 Start Date*: 2021-11-10
    Sponsor Name:ADIENNE SA
    Full Title: A phase II, randomized, double-blind, placebo-controlled, two-period, crossover trial to assess the efficacy and safety of begelomab in combination with standard steroid and/or immunosuppressant th...
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001799-39 Sponsor Protocol Number: CBAF312X2206 Start Date*: 2013-09-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active dermatomyositis.
    Medical condition: Active dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001398-34 Sponsor Protocol Number: BMMNC_PTA_001 Start Date*: 2016-06-15
    Sponsor Name:Institut klinické a experimentální medicíny
    Full Title: A prospective, randomized study to assess the effect of autologous bone marrow-derived mononuclear cell therapy and its combination with percutaneous transluminal angioplasty (PTA) in comparison wi...
    Medical condition: In our study, the effect of autologous cell therapy (ACT) will be compared with repeated percutaneous transluminal angioplasty (re-PTA) in patients with diabetic foot and then will be compared the ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10047065 - Vascular disorders 10062585 Peripheral arterial occlusive disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001397-15 Sponsor Protocol Number: BMMNC_CLI_001 Start Date*: 2016-06-15
    Sponsor Name:Institut klinické a experimentální medicíny
    Full Title: A prospective, randomized study to compare the effect on tissue oxygenation and clinical outcome of autologous bone marrow-derived mononuclear cell therapy with standard treatment in patients with ...
    Medical condition: Autologous cell therapy (ACT) is new technique for patients with critical limb ischemia and diabetic foot (DF). In our study, the effect of ACT and also the repetitive treatment will be compared wi...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10047065 - Vascular disorders 10034576 Peripheral ischaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015957-20 Sponsor Protocol Number: ARTEMIS Start Date*: 2010-02-16
    Sponsor Name:Karolinska University Hospital
    Full Title: Abatacept treatment in polymyositis and dermatomyositis
    Medical condition: polymyositis and dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036102 Polymyositis LLT
    12.1 10012503 Dermatomyositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) CZ (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005721-25 Sponsor Protocol Number: Lifetime Start Date*: 2023-07-05
    Sponsor Name:Univeristy Hospital Tuebingen
    Full Title: SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, placebo controlled, multi-center trial
    Medical condition: The study will include adult male and female patients with an early stage of chronic kidney disease (CKD stage G1A2/G2A2) and prediabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000137-52 Sponsor Protocol Number: IFN-K-005-DM Start Date*: 2016-07-26
    Sponsor Name:Neovacs SA
    Full Title: A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects with Dermatomyositis.
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA